rs4988321 — LRP5 Val667Met

LRP5 Val667Met — Bone Density's Genetic Regulator

Your skeleton is in a constant state of renovation. Every day, old bone is broken down by osteoclasts and replaced by new bone laid down by osteoblasts. What governs this process? In large part, a signaling cascade called the Wnt pathway¹¹ Wnt pathway
a highly conserved cellular communication system controlling cell proliferation, differentiation, and survival. LRP5 (low-density lipoprotein receptor-related protein 5) sits at the entry point of this pathway, acting as a co-receptor that captures Wnt proteins and relays their "build bone" message into cells. The Val667Met variant — so named because it swaps a valine amino acid for methionine at protein position 667 — subtly alters how efficiently this receptor does its job.

This variant is rare globally: the A (methionine) allele appears in about 4.7% of people of European descent, is exceptionally rare in East Asians (<0.1%), and is somewhat enriched in Ashkenazi Jewish populations (~9%). Homozygous AA individuals are extremely uncommon (~0.2%), making most genetic impact observable in AG heterozygotes.

The Mechanism

The Val667Met substitution falls in exon 10 of LRP5²² exon 10 of LRP5
one of four beta-propeller domains that bind Wnt pathway inhibitors and regulate receptor activation. The methionine substitution alters the local protein conformation within this propeller region, modestly reducing LRP5's ability to transduce Wnt signals into osteoblasts. With less Wnt signaling, osteoblasts receive a weaker "build bone" message throughout development and adult remodeling.

A 2023 functional study by Fabre et al.³³ Fabre et al.
using both human patients carrying the variant and transgenic mice engineered to express Val667Met demonstrated multiple downstream consequences: primary osteoblasts from variant mice showed diminished alkaline phosphatase activity and reduced mineralization capacity; bone matrix exhibited a lower hydroxyproline/proline ratio indicating compromised collagen cross-linking; and lumbar and hip BMD Z-scores were reduced in carrier patients. The pathway effect also extended to retinal vasculature — two patients showed vascular tortuosity, mirroring findings in LRP5 loss-of-function conditions.

The Evidence

The clearest population evidence comes from large male cohorts. Grundberg et al. 2008⁴⁴ Grundberg et al. 2008
combined three Scandinavian cohorts totaling 3,800 men and found that carriers of the Met allele had 3% lower lumbar spine BMD compared to non-carriers (p<0.05). The Odense Androgen Study (Brixen et al. 2007)⁵⁵ Odense Androgen Study (Brixen et al. 2007)
783 Caucasian men aged 20-30 found that each additional A allele was associated with a −0.26 Z-score change at the femoral neck (p=0.04) specifically in non-sedentary men, suggesting the variant's effect is most visible when bone is under mechanical load.

A key discovery emerged from a Greek postmenopausal cohort (Stathopoulou et al. 2010)⁶⁶ Greek postmenopausal cohort (Stathopoulou et al. 2010)
578 women followed for spine BMD and calcium intake patterns: A allele carriers had significantly lower spine BMD overall (p=0.002), but this effect was entirely confined to women consuming less than 680 mg calcium per day (p=0.001). Among women with higher calcium intake, the genotype difference disappeared — a textbook gene-nutrient interaction (interaction p=0.016) that points directly to a modifiable intervention.

The Framingham Offspring Cohort (Kiel et al. 2007)⁷⁷ Framingham Offspring Cohort (Kiel et al. 2007)
1,797 individuals with detailed exercise and BMD tracking found rs4988321 associated with Ward's triangle BMD (p=0.02) in younger men, with each rare allele changing BMD by 3-5%, and proposed the variant modulates how bone responds to mechanical loading via Wnt signaling.

Not all studies find significant associations: a Tunisian postmenopausal cohort and a Turkish osteoporosis study found no significant effect, suggesting the variant's impact may be attenuated in non-European populations and may depend on background genetic architecture, physical activity patterns, and lifetime calcium intake.

Practical Actions

The gene-nutrient interaction with calcium is actionable: if you carry the A allele, achieving calcium intakes above the level at which the association disappears in studies (roughly 700–800 mg/day from food and supplements combined) may blunt the genotypic disadvantage. Vitamin D is essential for calcium absorption, so ensuring adequate vitamin D status compounds this benefit. A BMD baseline measurement gives you a concrete data point to track over time and guides decisions about loading exercise regimens.

Interactions

The companion LRP5 variant rs3736228 (A1330V) affects the same Wnt co-receptor at a different domain and has similar effects on BMD. Individuals carrying risk alleles at both rs4988321 (Val667Met) and rs3736228 (A1330V) may have additive reduction in Wnt signaling and correspondingly greater BMD reduction, though published combined-genotype data are limited. The two variants appear to act independently in the same biological pathway. Additionally, since LRP5 mediates bone response to calcium and vitamin D signaling indirectly (via osteoblast differentiation), VDR variants (rs2228570, rs4588) that reduce vitamin D receptor efficiency may compound the BMD impact — though no single published study addresses all three loci together.